SUMMARY Lactulose is currently the drug of choice for the treatment of hepatic encephalopathy. It is, however, only available as a syrup which is contaminated with other sugars. Consequently patients may express aversion to its excessively sweet taste and many experience nausea because of its hyperosmolarity. Lactitol is a disaccharide analogue of lactulose which can be produced as a pure crystalline powder with a low relative sweetness. Theoretically it should have the same therapeutic effects as lactulose but fewer side effects. Five patients with chronic hepatic encephalopathy on maintenance lactulose were monitored clinically, psychometrically, and by measurement of venous blood ammonia, electroencephalogram mean cycle frequency, and cerebral blood flow during three months treatment with lactulose and a similar period on lactitol. Lactitol was at least as efficacious as lactulose but was more acceptable because its cathartic effect was more predictable, its formulation was more convenient and its less sweet taste preferred. Lactitol is the ideal successor to lactulose for treatment of this condition. 
encephalopathy and has been used successfully to treat one patient with this condition. 4 In the present study five patients with chronic hepatic encephalopathy, previously on long term maintenance therapy with lactulose, were treated with lactitol for three months under carefully monitored conditions. As close monitoring is known to have a beneficial effect on this condition, possibly because of better compliance with therapy, a monitored three month treatment period on lactulose was included for comparison.
Methods

PATIENTS
The study group comprised five patients with cirrhosis and chronic hepatic encephalopathy maintained in stable condition by use of protein restriction and oral lactulose ( Table 1 ). All five patients experienced worsening of their clinical condition, psychometric performance, and electroencephalogram mean cycle frequency if inadvertently allowed to become constipated or to discontinue protein restriction or lactulose. None of the alcoholic patients had abused alcohol for at least two years. All patients were admitted to hospital for 415 (Fig. 3) When assessed on maintenance lactulose all five patients showed reduction in cerebral blood flow to a mean of 33-0±4-9 ml/100 g brain/min (reference range 45±5 ml/100 g brain/min). After monitored treatment with lactulose for three months the mean cerebral blood flow remained unchanged, 32-5±3-9 ml/100 g brain/min, and little if any change was observed in individual measurements. After treatment with lactitol the mean cerebral blood flow remained low, 37-7±4-6 ml/100 g brain/min although a substantial increase in flow was observed in patients EH and NT.
PATIENTS ASSESSMENT (Table 3) Three patients, RG, JB, and EH considered lactitol to be as efficacious as lactulose, while patients LC and NT considered its effect superior. All five patients felt that treatment with lactitol was more acceptable. Stated reasons for the greater acceptability of lactitol included: (1) The cathartic effect of lactitol was more predictable. In order to achieve two semi-soft stools per day patients required a mean of 44 ml (range 20 to 100 ml) of lactulose or 64 g (48 to 84 g) of lactitol. All five patients found that stool frequency was more predictable with lactitol (Fig. 4) . (2) The formulation of lactitol was more convenient. Four patients were in full time employment and found lactitol more convenient to use during working hours; most added it to beverages or food as a sweetener. Patients LC, EH, and NT had avoided holidays while on maintenance lactulose because of difficulties experienced in transporting the The pathogenesis of this syndrome remains speculative. There is general agreement, however, that in the majority of instances hepatic encephalopathy is a metabolic/neurophysiological disorder of the brain and that gut produced toxins play a role in its genesis. 12 Treatment of the condition is therefore aimed, somewhat empirically, at reducing the production and absorption of these toxins and is achieved by decreasing the gut protein load, altering the intestinal flora, reducing the rate and absorption of protein and protein fragments, decreasing intestinal transit time and bowel cleansing.
The value of lactulose in the treatment of hepatic encephalopathy has been amply shown.2 This synthetic disaccharide is not absorbed but is hydrolysed by colonic bacteria principally to lactic and acetic acids. Its precise mode of action is uncertain but it might exert its beneficial effects by lowering colonic pH thereby reducing the absorption of un-ionised ammonia, by encouraging the incorporation of ammonia into bacterial protein, by decreasing intestinal transit time because of its cathartic effect or by an anti-endotoxin effect. 13 In general lactulose is an extremely safe drug although rarely it may produce profound diarrhoea and result in dehydration and hypernatraemia. 14 Lactulose is, however, only available as a very sweet syrup for which many patients express an aversion and as it is contaminated with other sugars it is hyperosmolar and may thus produce nausea, flatulence, and abdominal discomfort. Additionally even after prolonged usage its cathartic effects are not entirely predictable; therefore compliance with treatment may be poor.
Lactitol is a disaccharide analogue of lactulose which like the earlier compound is not absorbed in the small intestine but is extensively metabolised by colonic bacteria.3 Unlike lactulose, however, it is easily produced in a chemically pure form and can be dispensed as a powder which has a low relative sweetness.3 In theory it should be as effective as lactulose in the treatment of hepatic encephalopathy and its properties might confer additional benefits.
In the present study lactitol was given to five patients with chronic hepatic encephalopathy who had been maintained on long term lactulose.
Lactitol was at least as efficacious as lactulose in the treatment of this condition. All five patients, however, found treatment with lactitol more acceptable because its cathartic effect was more predictable, its formulation was more convenient and its less sweet taste was preferred. Lactitol would appear to be the ideal successor to lactulose for the treatment of hepatic encephalopathy. Further studies with this compound are justified. 
